Founded in 2005 in Portland, Oregon, UbiVac is a clinical-stage biotechnology company focused on developing therapeutic vaccines to combat cancer. Originating as a spinout from the Robert W. Franz Cancer Research Center at the Earle A. Chiles Research Institute within Providence Portland Medical Center, UbiVac aims to harness the body's immune system to target and eliminate cancer cells. The company's core mission is to innovate and advance immunotherapy treatments, with a vision to transform cancer care through cutting-edge vaccine technologies.
UbiVac has attracted notable affiliations, including leading oncologists and researchers from prestigious institutions. The company has secured investments from prominent venture capital firms and has achieved significant milestones in clinical trials, demonstrating promising results in cancer immunotherapy. UbiVac's impact extends beyond research, contributing to the broader scientific community through publications and collaborations, positioning itself as a key player in the fight against cancer.
